Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

2月18日， 万邦德 （002082.SZ）发布公告披露，其自主研发的甲钴胺治疗肌萎缩侧索硬化（ALS，渐冻症）获美国FDA孤儿药资格认定。这是继石杉碱甲系列产品获得FDA三项孤儿药及罕见儿科疾病认定后，公司在神经系统疾病治疗领域的又一重要突破，标志着其 创新药 研发能力获得国际权威认可，全球化战略布局进入加速期。

ALS is a progressive neurodegenerative disease that currently has no cure. Commonly known as Lou Gehrig’s disease, ALS ...

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.

Bain Capital said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare ...

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

Qure is planning soon to start enrolling patients in a second dose group as part of a clinical trial testing AMT-162 for SOD1 ...

Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone treatment, results of an administrative claims analysis show."Since ALS has ...

In a real-world study, In the end, researchers compared 395 ALS patients who'd been given Radicava against 395 matched controls who hadn't.

"Global pharma major Lupin Limited today announced that the United States Food and Drug Administration (U.S. FDA) has completed a Pre-Approval Inspection (PAI) of Edaravone Oral Suspension, 105 mg/ 5 ...

With zero observations, the US FDA has completed a pre-approval inspection of Edaravone oral suspension at its Somerset, New Jersey manufacturing facility. The inspection took place from January ...